Drug-Drug Interactions: Tenofovir with Boosted PI + Ledipasvir

Publish Date: 
Tuesday, March 17, 2015

It has been reported that the hepatitis C combination medication ledipasvir/sofosbuvir (LDV/SOF, Harvoni), and in particular the ledipasvir component, may increase tenofovir levels in the body. It also is known from previous investigations that ritonavir-boosted protease inhibitors (PIs) increase serum tenofovir concentrations. Thus, there has been a concern that coadministration of tenofovir with both ledipasvir and a boosted PI may increase the risk of renal toxicity.

Tenofovir-Containing ART as HBV Prophylaxis

Publish Date: 
Tuesday, March 17, 2015
Use of tenofovir as part of the ART regimen was associated with a sharply lower rate of HBV infection,

Switch to TDF/FTC from ABC/3TC Lowers Lipids

Publish Date: 
Tuesday, March 17, 2015
At week 12, all lipid measures had decreased in the switch group but not in the control group: total cholesterol dropped 33 mg/dL, LDL and triglycerides dropped 17-18 mg/dL, and HDL dropped 6 mg/dL. At week 24, similar changes were seen in the remaining patients switched to TDF/FTC. Authors report no changes in eGFR and no differences between groups in rates of proteinuria.

Bug Chasers: Gay Men and the Intentional Pursuit of HIV - A Narrative Analysis

Publish Date: 
Wednesday, February 4, 2015

Imagine you are sitting down with a dear friend that you haven’t seen in years because he ran away from an unloving, unsupportive home, from a town where he was different, picked on, and knew he could never be safe - at least that is how he felt, - to a place where he would find love, and the supportive family he so dearly wanted. He discloses that he is gay and living with HIV infection.  He says not to worry, that it’s ok, and then he says, “There’s more.”  You feel your heart beat faster and time suspends.

iCare: Evaluating the Usability of iPad Minis in the Clinical Setting

Publish Date: 
Wednesday, January 7, 2015

Technology is great…when it works. This phrase comes to mind every time technology is supposed to enhance an experience and a malfunction causes that experience to cease. We know that technology should have the capacity to transform our lives, including our lives as HIV care providers. But in order for it to do so, it has to work. It has to be usable (i.e. easy, reliable, and fast). While iPad Minis have been on the market for several years now, a review of the literature yielded no current studies to examine their usability or effectiveness in clinical use.

The HIV/AIDS Treatment Cascade in the U.S. Virgin Islands: Testing and Diagnosis in Paradise

Publish Date: 
Wednesday, December 3, 2014

virgin islandsQuite often when you think about the U.S. Virgin Islands (USVI), you envision a beautiful vacation on the beach drinking Pina Coladas, eating local food and listening to the sounds of island music. Although the Virgin Islands are truly paradise vacation spots, they are not free from the impact of HIV/AIDS. The three islands of St. Croix, St. Thomas, and St. John are unique and face their own challenges with testing, diagnosis, and treatment.

The National Quality Center Highlights Innovative Tools as it Celebrates its 10-Year Anniversary

Publish Date: 
Tuesday, December 16, 2014
In order to curtail new HIV infections and better reach—and engage—people living with HIV into care, providers have to evolve in the way that they do business. Performance measures are important indicators in ensuring effective provider practices and high-quality HIV care.
 
For the last 10 years the National Quality Center (NQC) has provided technical assistance to support Ryan White HIV/AIDS Program grantees by creating innovative services to meet their unique needs.

Pages

Subscribe to Sharespot RSS feed